Table 3 FDA-approved agents targeting the immune cells of the TME in B cell lymphomas
From: Insights into the tumor microenvironment of B cell lymphoma
Agent | Drug Category | Indication | Approval Year | Trials |
|---|---|---|---|---|
Pembrolizumab | CPI | Adult and pediatric patients with refractory PMBCL | 2018 | KEYNOTE-170 (NCT02576990) |
Lenalidomide | IMIDs | Previously treated FL and MZL | 2019 | AUGMENT (NCT01938001); MAGNIFY (NCT01996865) |
Lenalidomide | IMIDs | ASCT-ineligible R/R DLBCL patients | 2020 | L-MIND (NCT02399085); RE-MIND (NCT04150328) |
Umbralisib | PI3Ki | R/R MZL with at least one prior anti-CD20-based regimen; R/R FL with at least 3 prior lines of systemic therapy | 2021 | UTX-TGR-205 (NCT02793583) |
Zanubrutinib | BTKi | R/R MZL with at least one anti-CD20-based regimen | 2021 | BGB-3111-241 (NCT03846427); BGB-3111-AU-003 (NCT02343120) |